Skip to main content

Moricizine Pregnancy and Breastfeeding Warnings

Brand names: Ethmozine

Moricizine Pregnancy Warnings

Moricizine has been assigned to pregnancy category B by the FDA. Animal studies have revealed evidence of decreased maternal and fetal weight gain, possibly related to increased litter size, but failed to reveal evidence of embryo- or fetolethality. There are no controlled data in human pregnancy. Moricizine should be given during pregnancy only when need has been clearly established.

See references

Moricizine Breastfeeding Warnings

Moricizine is excreted into human milk. There are no reports on the effect of moricizine in nursing infants. Because of the potential for serious adverse effects in a nursing infant, a decision should be made whether to discontinue the drug or discontinue nursing, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. (2002) "Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals
  2. Page RL (1995) "Treatment of arrhythmias during pregnancy." Am Heart J, 130, p. 871-6

References for breastfeeding information

  1. (2002) "Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer